iShares US Pharmaceuticals ETF
209 hedge funds and large institutions have $732M invested in iShares US Pharmaceuticals ETF in 2026 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 56 increasing their positions, 52 reducing their positions, and 20 closing their positions.
100% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 20
11% more capital invested
Capital invested by funds: $658M → $732M (+$74.2M)
8% more funds holding
Funds holding: 194 → 209 (+15)
8% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 52
0.93% more ownership
Funds ownership: 66.11% → 67.04% (+0.93%)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$36.6M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$17.3M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$17.1M |
| 4 |
JP Morgan Chase
New York
|
+$16M |
| 5 |
Goldman Sachs
New York
|
+$9.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
Foundations Investment Advisors
Phoenix,
Arizona
|
-$61.8M |
| 2 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
-$24.8M |
| 3 |
MSCM
McElhenny Sheffield Capital Management
Dallas,
Texas
|
-$17.6M |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$8.1M |
| 5 |
PIWA
Prevail Innovative Wealth Advisors
Leawood,
Kansas
|
-$8.07M |
IHE Hedge Fund Activity: Q2 2026 in Review
209 of the 8,295 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2026, worth a combined $732M — up 11% from $658M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new IHE positions and 20 closed out — a net gain of 20 holders — while 56 added to existing stakes and 52 trimmed.
The largest buyer was Bank of America, adding an estimated $36.6M. The largest seller was Foundations Investment Advisors, cutting an estimated $61.8M.
- 209 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2026, up from 194 in Q1 2026.
- Funds reported $732M of iShares US Pharmaceuticals ETF stock for Q2 2026, up 11% quarter-over-quarter.
- 40 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2026 and 20 closed out, a net change of +20 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2026 was Bank of America, an estimated $36.6M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2026 was Foundations Investment Advisors, an estimated $61.8M sold.
Based on aggregated 13F filings for Q2 2026.